Recoxibright medical & product knowledge

pharma sales analysis

1. About us Efficacy GIT Tolerability CV Safety RECOXIBRIGHT Glossary About Elixir Vision, Mission & Values Recoxibright Efficacy GIT Tolerability CV Safety Pack and Price

2. About us Elixir Pharma is an Egyptian pharmaceutical company with a mission to provide every Egyptian patient with a cure to their illness or relief to their pain. Elixir has Latin, Greek, and Arabic origins and refers collectively to a potion with magical powers. This is because at Elixir Pharma, we believe that medications possess the power of managing disease and relieving pain. Elixir Pharma has taken onto its shoulder the goal of reaching the fine balance between quality and affordability. We, at Elixir Pharma, strive to apply international quality standards while maintaining local affordable prices Company Description Efficacy GIT Tolerability CV Safety RECOXIBRIGHT

3. About us To become the benchmark generic company in the Egyptian pharmaceutical market providing world-class and cost-effective products that satisfy our customer needs and recognize the passion of our employees and shareholders. Enhancing patients' lives. Efficacy GIT Tolerability CV Safety RECOXIBRIGHT Company Description

4. About us Amr Desouky CEO Hany Aly GM Efficacy GIT Tolerability CV Safety RECOXIBRIGHT Company Description

5. About us Efficacy GIT Tolerability CV Safety RECOXIBRIGHT Diclofenac 3 Daily Etoricoxib 1 Daily Etoricoxib 60 or 90 mg Once Daily Diclofenac 50 mg 3 Times Daily (p < 0.05) As effective As Rexcoibright ( Etoricoxib ) once daily provided a clinical effect that was similar to that of diclofenac 150 mg in patients with OA and was maintained for up to 52 weeks. The long-term efficacy and tolerability of Etoricoxib in osteoarthritis patients 1

6. About us Efficacy GIT Tolerability CV Safety RECOXIBRIGHT MEDAL a long-term program in patients with OA and RA 2 Cumulative Incidence of Confirmed Upper GI Events (Perforations, Ulcers, and Bleeds) Etoricoxib 60 and 90 mg showed Tolerability and superior GI safety based on PUS vs. Diclofenac 150 mg

7. About us Efficacy GIT Tolerability CV Safety RECOXIBRIGHT Cumulative incidence of confirmed thrombotic CV events in the MEDAL Program 1 Cumulative incidence, % (95% CI) Etoricoxib Diclofenac Months Etoricoxib 60 and 90 mg, pooled (320 events) Diclofenac 150 mg (323 events) The results of the MEDAL Program demonstrated that the rates of thrombotic CV events among arthritis patients who received the selective COX-2 inhibitor Recoxibright ( Etoricoxib ) were comparable with those among patients who received Diclofenac MEDAL a long-term program in patients with OA and RA 2

8. About us Who Are we Portfolio Quality RECOXIBRIGHT The Strength to Continue

9. About us Who Are we Portfolio Quality RECOXIBRIGHT The Strength to Continue Price Monthly Cost: 169.50 EGP Strip: 56.50 EGP

10. About us Who Are we Portfolio Quality RECOXIBRIGHT The Strength to Continue Curtis SP, Bockow B, Fisher C, et al. Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, activecomparator controlled trial [NCT00242489 ] BMC Musculoskelet Disord . 2005; 6 :58. Cannon CP, Curtis SP, FitzGerald GA , etal . for MEDAL Steering Committee. Cardiovascular outcomes with etoricoxiband diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Longterm (MEDAL) programme : a randomized comparison. Lancet. 2006;368(9549):1771-1781. https://www.drugbank.ca/drugs/DB01628 Recoxibrigh PIL